Biotechnology

Zai Lab

Zai Lab CEO Du Ying Sells 100k ADS for $1.99 Million

HKEX Discloses Goldman Sachs Reduced Zai Lab Stake to 6.67%

CICC: Zai Labs Q1 Results In Line, Downgrades 2026-2027 Profit Forecasts and Target Prices

Zai Lab Chairman Du Ying Sells $2.02M in ADS Shares, Holding Drops to 1.12 Million

Zai Lab's Drug Zoci Receives FDA Fast Track Designation for the Treatment of Extracranial Neuroendocrine Carcinoma

BOC International Downgrades Zai Lab's Rating and Target Price

Zai Lab released FY2026 Q1 earnings on May 7 Pre-Market EST, actual revenue USD 99.61 M (forecast USD 108.43 M), actual EPS USD -0.4606 (forecast USD -0.5646)

Zai Lab Announces Q1 2026 Financial Results and R&D Progress

Zai Lab Q1 2026 Revenue Misses Expectations

Zai Lab to Release FY2026 Q1 Earnings on May 7 Pre-Market EST, Forecast Revenue USD 112.59 M, EPS USD -0.5279

BOA Securities Upgrades Revenue Forecasts for Zai Lab

Zai Lab Shifts Focus to Global Innovation Pipeline Valuation

UBS Downgrades Zai Lab's Q1 Sales Forecast but Raises Price Target

Zai Lab Announces Early Clinical Results of DLL3-targeted Antibody Drug Conjugate

RA Capital and RTW Investments Massive Investment in Zai Lab

Zai Lab Partners with Amgen for DLL3 Targeting ADC Clinical Trial

Zai Lab Reports FY2025 Results: Revenue Up, Net Loss Down

Zai Lab to release FY2025 earnings on March 27 After-Market EST, forecast revenue USD 467.77 M, EPS USD -1.6787

BOA Securities Cuts Revenue Forecast for Zai Lab But Raises Target Price

Guotai Junan Maintains Overweight Rating on Zai Lab with Price Target

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Zai Lab Limited (ZLAB.US/09688.HK) Q3 2025 Earnings Conference Call

Zai Lab Limited (ZLAB.US/09688.HK) Q1 2025 Earnings Conference Call

Zai Lab Limited (ZLAB.US/09688.HK) Q4 2024 Earnings Conference Call

ZLAB

LABU

CICC has reduced ZAI LAB's target price to HKD20.2 following a report indicating a 6% YoY revenue decline to USD99.6 million and a net loss of USD51 million in 1Q. The results met expectations. The broker highlighted ongoing Phase III trials and multiple candidates entering clinical stages. CICC adjusted its 2026 and 2027 earnings forecasts, predicting larger net losses, while maintaining an Outperform rating.

- CICC reported that ZAI LAB (09688.HK) had a revenue of USD 99.6 million in Q1, a 6% YoY decline, with a net loss of USD 51 million, aligning with expectations.  
- The company is advancing its pipeline, with Zoci in Phase III trials and ZL1503 and ZL6201 in earlier clinical stages, while recent earnings forecasts have been downgraded due to competitive pricing pressures.  
- CICC lowered the 2026 net loss projection for ZAI LAB from USD 226 million to USD 248 million and maintained an Outperform rating, reducing the target price by 8%.

AASTOCKS News

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

iShares Biotechnology ETF

iShares US Pharma

Direxion S&P Biotech Bull 3X

VG Health

ZAI LAB

CICC

CICC Cuts ZAI LAB  TP to HKD20.2; 1Q Results In Line

VNET

RERE

MVST

SOHU

Chaince Digital(CD) rose 26.54%, with a trading turnover 3.5 Million USD, and a year-to-date rose 111.1%. Tencent Music(TME) rose 6.97%, with a trading turnover 151.8 Million USD, and a year-to-date fell 46.9%. Niu Tech (NIU) fell 14.96%, with a trading turnover 3.2 Million USD, and a year-to-date fell 20.3%. Microvast(MVST) fell 11.97%, with a trading turnover 10.5 Million USD, and a year-to-date fell 55.4%.

- The Nasdaq Composite Index decreased by 0.51%, with a year-to-date increase of 12.3%.  
- The S&P 500 Index fell by 0.07%, rising 8.1% over the year, while the Dow Jones Industrial Average rose by 0.32%, up 3.4% year-to-date.  
- Chaince Digital saw a significant increase of 26.54%, with a total trading volume of $3.519 million and a year-to-date gain of 111.1%.

Top Gainers&Losers

Chaince Digital

Tencent Music

Vnet

ATRenew

GigaCloud Tech

Niu Tech 

Microvast

Sohu.com

Li Auto

Top 5 CDRs Gainers/Losers (>100M) (5.18)

Japan’s MHLW has approved Boehringer's Jascayd, the first PDE4B inhibitor for treating IPF and PPF. This approval follows successful Phase III trials showing significant lung function improvement and a 59% reduction in death risk. Boehringer's chairman highlighted this as a crucial advancement for patients, providing a new oral treatment option after over a decade. Additionally, Boehringer is collaborating with Zai Lab on a new cancer treatment approach.

- Jascayd is the first phosphodiesterase 4B (PDE4B) inhibitor approved for antifibrotic and immunomodulatory uses, with Japan being the fourth country to authorize it.  
- The approval follows the Phase III FIBRONEER-IPF and FIBRONEER-ILD trials, where Jascayd demonstrated a slower decline in lung function and a 59% reduction in death risk compared to placebo.  
- Boehringer Ingelheim emphasized the significance of this approval, offering a new oral treatment option for patients with idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PPF).

Pharmaceutical Business Review

Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF

09688

159570

Hong Kong's innovative drug sector continues to experience a downturn, with Zai Labdropping over 6% and Jiangsu Hengrui Medicinefalling more than 4%. According to Jin10, other companies such as CSPC Pharmaceutical Groupand WuXi AppTecalso saw declines.

CoinLive

China Universal CNI HK Connect Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

Huaan Hang Seng Biotech ETF

Minsheng Royal CSI Biotechnology Theme ETF

China Universal 800 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

Hwabao WP CSI Pharmaceuticals ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund Hang Seng SCHK Innovative Drug ETF

HENGRUI PHARMA

CSPC PHARMA

WUXI APPTEC

WuXi AppTec

STOCKS | Hong Kong's Innovative Drug Sector Declines

Ying Du, Director, Chairperson & CEO of Zai Lab, sold 100,000 shares for $2,003,044 on May 13, 2026. Following the SEC Form 4 filing, Du now controls 1,122,626 American depositary shares of the company.

- Ying Du, Director, Chairperson & CEO of Zai Lab, sold 100,000 shares for $2,003,044 on May 13, 2026.  
- Following this transaction, Du retains control over 1,122,626 American depositary shares of the company.  
- The sale was reported in a Form 4 filing with the SEC.

Fidelity

Zai Lab Insider Sold Shares Worth $2,003,044, According to a Recent SEC Filing

ARKG

Zai Lab Ltd has granted share options and restricted share units under its 2024 Equity Incentive Plan, issuing 136,819 American depositary shares in options to one employee and 75,288 ADS-equivalent restricted share units to four employees. The options have a 10-year term and a four-year vesting schedule, priced at US$20.32 per ADS. This initiative aims to align employee incentives with shareholder interests and enhance talent retention as the company navigates the biopharmaceutical market. The current analyst rating for Zai Lab stock is a Hold with a price target of HK$18.00.

- Zai Lab Ltd has issued 136,819 share options and 75,288 restricted share units to employees under its 2024 Equity Incentive Plan.  
- The options are priced at US$20.32 per American depositary share, just above the closing price of US$19.59, with a 10-year term and four-year vesting.  
- This initiative aims to enhance employee retention, align management with shareholder interests, and support Zai Lab's growth in the global biopharmaceutical market.

Tip Ranks

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Zai Lab Grants New Share Options and RSUs Under 2024 Equity Plan

BOCI has downgraded ZAI LABfrom Buy to Hold, reducing its target price from HKD35 to HKD17 due to weak Q1 results, with revenue down 6% YoY to USD99.6 million, falling short of expectations. The company reported a net loss of USD51 million, attributed to declining Zejula sales and medical insurance price cuts. BOCI has revised its revenue forecasts for the next three years to USD470 million, USD620 million, and USD780 million, citing limited visibility on mid-term profitability and high commercialization risks.

- BOCI reported that ZAI LAB experienced a 6% year-on-year revenue decline to USD 99.6 million, below market expectations, primarily due to reduced Zejula sales and medical insurance price cuts for Efgartigimod.  
- Continued R&D investments have widened the net loss to USD 51 million, with management anticipating slow revenue improvement in 2026 and a return to growth likely in 2027.  
- Consequently, BOCI has significantly reduced its revenue forecasts and target price for ZAI LAB, downgrading its rating from Buy to Hold, citing high commercialization and execution risks.

BOCI Downgrades ZAI LAB  to Hold, Halves TP to HKD17

M Stanley has revised its target price for ZAI LABfrom HKD19.5 to HKD19, maintaining an Overweight rating. This adjustment follows updates to its financial model after the company's 1Q results, leading to a 5% reduction in revenue forecasts for 2026-2028. M Stanley projects ZAI LAB's 2026 revenue at USD488 million, with adjusted loss per share forecasts for 2026-2028. The broker notes that the impact of the target price cut is limited due to the reliance on terminal value in DCF models for biotech valuations.

- M Stanley updated its risk-reward assessment on ZAI LAB (09688.HK), lowering the target price from HKD 19.5 to HKD 19 while maintaining an Overweight rating.  
- This adjustment is based on financial model updates following the company’s 1Q results, resulting in a 5% revenue forecast reduction for 2026 to 2028.  
- M Stanley projects ZAI LAB’s 2026 revenue at USD 488 million and has revised its 2026-2028 loss per share forecasts upward, reflecting anticipated changes in biotech stock valuations.

Morgan Stanley

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

M Stanley Cuts ZAI LAB  TP to HKD19, Reflecting Post-1Q Results Forecast Revisions

IBBQ

In a report released on May 7, from UBS maintained a Buy rating on Zai Lab Ltd, with a price target of HK$27.00. The company’s shares closed last Thursday at HK$16.20.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zai Lab Ltd with a €3.04 average price target.

- UBS maintained a Buy rating on Zai Lab Ltd, setting a price target of HK$27.00.  
- The company's shares closed at HK$16.20 on the previous Thursday.  
- There is a Strong Buy analyst consensus for Zai Lab Ltd, with an average price target of €3.04.

Zai Lab(ZLAB.US)

CICC Cuts ZAI LAB TP to HKD20.2; 1Q Results In Line

Top 5 CDRs Gainers/Losers (>100M) (5.18)

Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF

STOCKS | Hong Kong's Innovative Drug Sector Declines

Zai Lab Insider Sold Shares Worth $2,003,044, According to a Recent SEC Filing

Zai Lab Grants New Share Options and RSUs Under 2024 Equity Plan

BOCI Downgrades ZAI LAB to Hold, Halves TP to HKD17

M Stanley Cuts ZAI LAB TP to HKD19, Reflecting Post-1Q Results Forecast Revisions

UBS Reaffirms Their Buy Rating on Zai Lab Ltd (1ZLB)